Prelude Therapeutics reports third quarter net loss of $19.7 million
Reuters
Nov 12
Prelude <a href="https://laohu8.com/S/LENZ">Therapeutics</a> reports third quarter net loss of $19.7 million
Prelude Therapeutics Inc. reported a net loss of $19.7 million, or $0.26 per share, for the three months ended September 30, 2025, compared to $32.3 million, or $0.43 per share, for the same period in 2024. Non-cash expenses related to share-based payments were $2.4 million, down from $5.9 million in the prior year period. As of September 30, 2025, cash, cash equivalents, restricted cash and marketable securities totaled $58.2 million. The company subsequently received an additional license payment from AbCellera in October 2025 and $60.0 million from Incyte in November 2025. Prelude anticipates that its current funds will support operations into 2027. The company also presented new preclinical data at the European Hematology Association 2025 Congress and will present updated data at the American Society of Hematology Annual Meeting in December 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prelude Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9573804-en) on November 12, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.